These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 19926405)

  • 81. Acute hepatitis C in patients receiving hemodialysis.
    Griveas I; Germanidis G; Visvardis G; Morice Y; Perelson AS; Pawlotsky JM; Papadopoulou D
    Ren Fail; 2007; 29(6):731-6. PubMed ID: 17763169
    [TBL] [Abstract][Full Text] [Related]  

  • 82. What is the cost-effectiveness of hepatitis C treatment for injecting drug users on methadone maintenance in New Zealand?
    Sheerin IG; Green FT; Sellman JD
    Drug Alcohol Rev; 2004 Sep; 23(3):261-72. PubMed ID: 15370005
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Multicenter study of pegylated interferon α-2a monotherapy for hepatitis C virus-infected patients on hemodialysis: REACH study.
    Kikuchi K; Akiba T; Nitta K; Masakane I; Ando R; Izumi N; Atsukawa M; Yamazaki C; Kato F; Hotta N; Tominaga Y; Orito E; Hora K; Nagasawa M; Kasahara H; Kawaguchi M; Kimura H; Ikebe N; Kawanishi H; Moriishi M; Shigemoto K; Harada T; Hirakata H; Watanabe H; Nosaki T; Tsubouchi H; Imawari M; Akizawa T
    Ther Apher Dial; 2014 Dec; 18(6):603-11. PubMed ID: 25196061
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Viral kinetics in hepatitis C or hepatitis C/human immunodeficiency virus-infected patients.
    Sherman KE; Shire NJ; Rouster SD; Peters MG; James Koziel M; Chung RT; Horn PS
    Gastroenterology; 2005 Feb; 128(2):313-27. PubMed ID: 15685543
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Successful treatment of chronic hepatitis C with pegylated interferon in combination with ribavirin in a methadone maintenance treatment program.
    Litwin AH; Harris KA; Nahvi S; Zamor PJ; Soloway IJ; Tenore PL; Kaswan D; Gourevitch MN; Arnsten JH
    J Subst Abuse Treat; 2009 Jul; 37(1):32-40. PubMed ID: 19038524
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Methadone maintenance and hepatitis C virus infection among injecting drug users.
    Crofts N; Nigro L; Oman K; Stevenson E; Sherman J
    Addiction; 1997 Aug; 92(8):999-1005. PubMed ID: 9376782
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Incidence of hepatitis C virus infection in the prison setting: The SToP-C study.
    Hajarizadeh B; Carson JM; Byrne M; Grebely J; Cunningham E; Amin J; Vickerman P; Martin NK; Treloar C; Martinello M; Lloyd AR; Dore GJ;
    J Viral Hepat; 2024 Jan; 31(1):21-34. PubMed ID: 37936544
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Factors associated with early virological response to peginterferon-α-2a/ribavirin in chronic hepatitis C.
    García-Samaniego J; Romero M; Granados R; Alemán R; Jorge Juan M; Suárez D; Pérez R; Castellano G; González-Portela C
    World J Gastroenterol; 2013 Mar; 19(12):1943-52. PubMed ID: 23569340
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Reduction in neutrophil count during hepatitis C treatment: drug toxicity or predictor of good response?
    Alvarez-Uria G; Day JN; Nasir AJ; Russell SK; Vilar FJ
    Dig Dis Sci; 2010 Jul; 55(7):2058-62. PubMed ID: 19757045
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Rationale and design of a randomized controlled trial of directly observed hepatitis C treatment delivered in methadone clinics.
    Litwin AH; Berg KM; Li X; Hidalgo J; Arnsten JH
    BMC Infect Dis; 2011 Nov; 11():315. PubMed ID: 22078241
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Positive impact of hepatitis C virus (HCV) treatment on antiretroviral treatment adherence in human immunodeficiency virus-HCV coinfected patients: one more argument for expanded access to HCV treatment for injecting drug users.
    Roux P; Fugon L; Winnock M; Salmon-Céron D; Lacombe K; Sogni P; Spire B; Dabis F; Carrieri MP;
    Addiction; 2012 Jan; 107(1):152-9. PubMed ID: 21819472
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Sustained virological response: a milestone in the treatment of chronic hepatitis C.
    Morisco F; Granata R; Stroffolini T; Guarino M; Donnarumma L; Gaeta L; Loperto I; Gentile I; Auriemma F; Caporaso N
    World J Gastroenterol; 2013 May; 19(18):2793-8. PubMed ID: 23687416
    [TBL] [Abstract][Full Text] [Related]  

  • 93. An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response.
    Mangia A; Thompson AJ; Santoro R; Piazzolla V; Tillmann HL; Patel K; Shianna KV; Mottola L; Petruzzellis D; Bacca D; Carretta V; Minerva N; Goldstein DB; McHutchison JG
    Gastroenterology; 2010 Sep; 139(3):821-7, 827.e1. PubMed ID: 20621700
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Hepatitis C virus cascade of care among people who inject drugs in Australia: Factors associated with testing and treatment in a universal healthcare system.
    Gibbs D; Price O; Grebely J; Larney S; Sutherland R; Read P; Butler K; Degenhardt L; Peacock A
    Drug Alcohol Depend; 2021 Nov; 228():109050. PubMed ID: 34607193
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Progress Towards Elimination of Hepatitis C Infection Among People Who Inject Drugs in Australia: The ETHOS Engage Study.
    Valerio H; Alavi M; Silk D; Treloar C; Martinello M; Milat A; Dunlop A; Holden J; Henderson C; Amin J; Read P; Marks P; Degenhardt L; Hayllar J; Reid D; Gorton C; Lam T; Dore GJ; Grebely J
    Clin Infect Dis; 2021 Jul; 73(1):e69-e78. PubMed ID: 32421194
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Current practice of hepatitis C treatment in Southern Italy.
    Stroffolini T; Spadaro A; Guadagnino V; Cosentino S; Fatuzzo F; Galdieri A; Cacopardo B; Scalisi I; Sapienza M; Russello M; Scifo G; Frugiuele P; Foti G; Almasio PL;
    Dig Liver Dis; 2010 Nov; 42(11):822-5. PubMed ID: 20435532
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Peer support in small towns: A decentralized mobile Hepatitis C virus clinic for people who inject drugs.
    Midgard H; Bjørnestad R; Egeland M; Dahl E; Finbråten AK; Kielland KB; Blindheim M; Dalgard O
    Liver Int; 2022 Jun; 42(6):1268-1277. PubMed ID: 35362660
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Factors associated with sustained virological response in liver transplant recipients with recurrent hepatitis C.
    Pillai AA; Lee VS; Wang E; Rinella ME; Levitsky J
    Transplant Proc; 2010 Nov; 42(9):3647-51. PubMed ID: 21094833
    [TBL] [Abstract][Full Text] [Related]  

  • 99. HIV/Hepatitis C virus-coinfected virologic responders to pegylated interferon and ribavirin therapy more frequently incur interferon-related adverse events than nonresponders do.
    Osinusi A; Rasimas JJ; Bishop R; Proschan M; McLaughlin M; Murphy A; Cortez KJ; Polis MA; Masur H; Rosenstein D; Kottilil S
    J Acquir Immune Defic Syndr; 2010 Mar; 53(3):357-63. PubMed ID: 20101190
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Rapid Prediction of Treatment Futility of Boceprevir with Peginterferon-Ribavirin for Taiwanese Treatment Experienced Hepatitis C Virus Genotype 1-Infected Patients.
    Yang CC; Tsai WL; Su WW; Huang CF; Cheng PN; Lo CC; Tseng KC; Mo LR; Wang CH; Hsu SJ; Lai HC; Su CW; Liu CJ; Peng CY; Yu ML
    PLoS One; 2015; 10(9):e0137852. PubMed ID: 26368130
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.